Biology subjects

Wraith, D. C.

Publications and source records attributed to Wraith, D. C..

4 recordsLinked to original sources

bioRxiv2024

Remote force modulation of the T-cell receptor reveals an NFAT-threshold for CD4+ T cell activation

Abstract/SummaryMechano-modulation of cell surface proteins to influence cell activation has been shown as a promising new advanced therapy for regenerative medicine applications. These strategies rely on the manipulation of mechanosensitive cell surface receptors to initiate intracellular signal transduction. The cell surface receptor of T lymphocytes (TCR), which recognises peptide-MHC molecules central to driving the adaptive immune response, has recently been suggested to be mechano-responsive. Despite this advance, little is known as to whether the TCR can be mechanically modulated to achieve TCR signalling and subsequent T cell activation, and whether these characteristics can be exploited for immunotherapies. Here, we describe a magnetic particle-based platform for mechanical modulation of the TCR and outline how this platform can be utilised to achieve CD4+ T cell activation. We demonstrate that mechanical manipulation of the TCR induces cell surface clustering of the TCR and downstream TCR signalling, leading to eventual TCR downregulation and T cell activation. We investigate the temporal relationship between mechanical modulation of the TCR and subsequent T cell activation, hereby identifying that accumulation of signalling events within the NFAT-pathway is required to reach the threshold required for CD4+ T cell activation, outlining an axis which controls the CD4+ T cell response to external mechanical cues. These findings identify how CD4+ T cells can modulate their function in response to such cues, whilst also outlining a remote-magnetic particle-based platform that may be used for the control of T cell responses.

immunology↗

bioRxiv2024

Interferonγ and IL-27 positively regulate type 1 regulatory T-cell development during adaptive tolerance

Strong T-cell receptor (TCR) and IL-27 signalling influence type-1 regulatory (Tr1) T-cell development but whether other signals determine their differentiation is unclear. Utilising Tg4 TCR transgenic mice we established a model for rapid Tr1 cell induction. A single high dose of [4Y]-MBP peptide drove the differentiation of Il10+ T-cells with bona fide Tr1 cell protein and mRNA signatures. Kinetic transcriptional analysis revealed that the Tr1 cell module was transient and preceded by a burst of Ifng transcription in CD4+ T-cells. Neutralisation of IFN{gamma} reduced Tr1 cell frequency and strong TCR signalling markers, which was correlated with reduced macrophage activation. Antibody depletion experiments inferred that T-cells - but not NK cells - provided the relevant source of IFN{gamma}. Additionally, we show that blocking IL-27 in combination with IFN{gamma} neutralisation additively reduced Tr1 cell frequency in vivo. These findings reveal that during strong tolerogenic TCR signalling IFN-{gamma} has a non-redundant regulatory role in augmenting the differentiation of Tr1 cells in vivo.

immunology↗

bioRxiv2021

Antigen and Checkpoint Receptor Recalibration of T Cell Receptor Signal Strength

How T cell receptor (TCR) signal strength modulates T cell function and to what extent this is modified by immune checkpoint blockade (ICB) are key questions in immunology. Using Nr4a3-Tocky mice as a digital read-out of NFAT pathway activity, we identify the rapid quantitative and qualitative changes that occur in CD4+ T cells in response to a range of TCR signalling strengths. We demonstrate that the time and dose dependent programming of distinct co-inhibitory receptors rapidly re-calibrates T cell activation thresholds. By developing a new in vivo model, we analyse the immediate effects of ICB on T cell re-activation. Our findings reveal that anti-PD1 but not anti-Lag3 immunotherapy leads to an increased TCR signal strength. We define a strong TCR signal metric of five genes specifically upregulated by anti-PD1 in T cells (TCR.strong), which can stratify clinical outcomes during anti-PD1 monotherapy in melanoma patients. Our study therefore reveals how analysis of TCR signal strength - and its manipulation - can provide powerful metrics for monitoring outcomes to immunotherapy. Key PointsO_LITCR signal strength-dependent programming of CD4+ T cells revealed over time in vivo C_LIO_LIInhibitory receptor expression is dynamic, TCR signal strength dependent, and rapidly re-calibrates T cell activation thresholds C_LIO_LIPD1 but not Lag3 blockade leads to a unique and increased TCR signal strength signature (coined TCR.strong) C_LIO_LITCR.strong metric stratifies melanoma patient survival in response to Nivolumab (anti-PD1) therapy C_LI

immunology↗

bioRxiv2019

Distinct regulation of Nr4a receptors by NFAT and ERK signalling during T cell activation

Nr4a receptors are activated by T cell receptor (TCR) and B cell receptor (BCR) signalling and play key roles in T cell differentiation and promoting T cell exhaustion. How TCR signalling pathways regulate Nr4a receptors and their sensitivities to different physiological types of TCR signalling (e.g. tonic versus activating) remains unknown. Here we utilise Nr4a1/Nur77-GFP and Nr4a3-Tocky mice to elucidate the signalling pathways that govern Nr4a receptor expression in CD4+ and CD8+ T cells. Our findings reveal that Nr4a1-3 are Src family kinase-dependent. Moreover, Nr4a2 and Nr4a3 are abolished by calcineurin inhibitors and bind NFAT1, highlighting a necessary and sufficient role for NFAT in the control of Nr4a2 and Nr4a3, but redundancy for NFAT for Nr4a1. During T cell development, Nr4a1 is activated by tonic signalling during TCR-beta selection in the thymus, whilst Nr4a3 requires cognate peptide:MHC interactions for expression. Thus, due to differential sensitivity of Nr4a1 and Nr4a3 to TCR signalling pathways, T cells undergoing tonic versus activating TCR signalling events can be distinguished in vivo.

immunology↗